Last reviewed · How we verify

NCT04158102

Evaluate the Pharmacokinetics and Safety of EXPAREL® Following Subcutaneous Administration in Healthy Chinese Subjects

Completed Phase 1 Last updated 18 January 2020
What this trial tests

Phase 1 trial testing Bupivacaine liposome injectable suspension in Healthy Subjects in 20 participants. Completed in 26 December 2019.

Timeline
7 November 2019
Primary endpoint
17 December 2019
26 December 2019

Quick facts

Lead sponsorNuance Pharma (shanghai) Co., Ltd
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment20
Start date7 November 2019
Primary completion17 December 2019
Estimated completion26 December 2019
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Nuance Pharma (shanghai) Co., Ltd

Who can join

Adults 18 to 55, any sex, with Healthy Subjects. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-center, open-label, single-dose study to evaluate the safety, pharmacokinetics in healthy subjects

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Pharmacokinetics and safety of liposomal bupivacaine after local infiltration in healthy Chinese adults: a phase 1 study.
    Cheung BM, Ng PY, Liu Y, Zhou M, et al · · 2021 · cited 11× · PMID 34315419 · DOI 10.1186/s12871-021-01407-5

Verify or expand the search:

Other trials of Bupivacaine liposome injectable suspension

Trials testing the same drug.

Other recruiting trials for Healthy Subjects

Currently open trials in the same condition.

Other Nuance Pharma (shanghai) Co., Ltd trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04158102.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing